Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor

C. Pizzini, M. Mussap, P. Mangiarotti, M. Plebani, R. Selmin, V. Fanos

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: To determine the effects of cefaclor prophylaxis on sensitive urinary biomarkers of renal tubular damage in children with recurrent urinary tract infections. Design: Urinary levels of α1-microglobulin (α1-m) and N-acetyl-β-D-glucosaminidase (NAG) were compared in children with recurrent urinary tract infections on antibacterial prophylaxis with cefaclor and in an untreated control group. Setting: A university paediatric department; patients were followed in a day hospital. Participants and Interventions: Thirty-eight patients (20 males and 18 females aged from 1 to 12 years) with at least two episodes of urinary tract infections in the previous 2 months received cefaclor (20 mg/kg/day in a single bedtime dose) for a minimum of 2 months. After 1 month of treatment all patients underwent BUN and serum creatinine, urine analysis and urine cultures, renal ultrasonography (found to be normal in all cases) and voiding urethrocystography (six cases of vesicoureteric reflux were observed). Results were compared with those from a healthy age-matched untreated control group of 36 children. Main Outcome Measures and Results: In the 32 patients without vesicoureteric reflux, the NAG value was 1.44 ± 1.77 U/mmol creatinine, while the α1-m value was 2.10 ± 1.67 U/mmol creatinine. No significant difference in these parameters was found versus the upper limit of control values (mean values + 2 SD: 1 and 1.6 U/mmol creatinine, respectively). In the six patients who had vesicoureteric reflux, NAG and α1-m values were significantly higher than in controls (p <0.05): 3.08 ± 4.09 and 2.85 ± 3.71 U/mmol creatinine, respectively. Conclusions: Cefaclor prophylaxis was well tolerated at the renal level in children with recurrent urinary tract infections. However, urinary biomarker excretion is increased in the presence of vesicoureteric reflux.

Original languageEnglish
Pages (from-to)461-466
Number of pages6
JournalClinical Drug Investigation
Volume18
Issue number6
Publication statusPublished - 1999

Fingerprint

Cefaclor
Urinary Tract Infections
Creatinine
Hexosaminidases
Biomarkers
Kidney
Urine
Control Groups
Blood Urea Nitrogen
Ultrasonography
Outcome Assessment (Health Care)
Pediatrics
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pizzini, C., Mussap, M., Mangiarotti, P., Plebani, M., Selmin, R., & Fanos, V. (1999). Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor. Clinical Drug Investigation, 18(6), 461-466.

Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor. / Pizzini, C.; Mussap, M.; Mangiarotti, P.; Plebani, M.; Selmin, R.; Fanos, V.

In: Clinical Drug Investigation, Vol. 18, No. 6, 1999, p. 461-466.

Research output: Contribution to journalArticle

Pizzini, C, Mussap, M, Mangiarotti, P, Plebani, M, Selmin, R & Fanos, V 1999, 'Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor', Clinical Drug Investigation, vol. 18, no. 6, pp. 461-466.
Pizzini, C. ; Mussap, M. ; Mangiarotti, P. ; Plebani, M. ; Selmin, R. ; Fanos, V. / Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor. In: Clinical Drug Investigation. 1999 ; Vol. 18, No. 6. pp. 461-466.
@article{daa62c4b331f435e9c5f62988242fcdf,
title = "Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor",
abstract = "Objective: To determine the effects of cefaclor prophylaxis on sensitive urinary biomarkers of renal tubular damage in children with recurrent urinary tract infections. Design: Urinary levels of α1-microglobulin (α1-m) and N-acetyl-β-D-glucosaminidase (NAG) were compared in children with recurrent urinary tract infections on antibacterial prophylaxis with cefaclor and in an untreated control group. Setting: A university paediatric department; patients were followed in a day hospital. Participants and Interventions: Thirty-eight patients (20 males and 18 females aged from 1 to 12 years) with at least two episodes of urinary tract infections in the previous 2 months received cefaclor (20 mg/kg/day in a single bedtime dose) for a minimum of 2 months. After 1 month of treatment all patients underwent BUN and serum creatinine, urine analysis and urine cultures, renal ultrasonography (found to be normal in all cases) and voiding urethrocystography (six cases of vesicoureteric reflux were observed). Results were compared with those from a healthy age-matched untreated control group of 36 children. Main Outcome Measures and Results: In the 32 patients without vesicoureteric reflux, the NAG value was 1.44 ± 1.77 U/mmol creatinine, while the α1-m value was 2.10 ± 1.67 U/mmol creatinine. No significant difference in these parameters was found versus the upper limit of control values (mean values + 2 SD: 1 and 1.6 U/mmol creatinine, respectively). In the six patients who had vesicoureteric reflux, NAG and α1-m values were significantly higher than in controls (p <0.05): 3.08 ± 4.09 and 2.85 ± 3.71 U/mmol creatinine, respectively. Conclusions: Cefaclor prophylaxis was well tolerated at the renal level in children with recurrent urinary tract infections. However, urinary biomarker excretion is increased in the presence of vesicoureteric reflux.",
author = "C. Pizzini and M. Mussap and P. Mangiarotti and M. Plebani and R. Selmin and V. Fanos",
year = "1999",
language = "English",
volume = "18",
pages = "461--466",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Urinary biomarkers in children with urinary tract infections with and without reflux on antibacterial prophylaxis with cefaclor

AU - Pizzini, C.

AU - Mussap, M.

AU - Mangiarotti, P.

AU - Plebani, M.

AU - Selmin, R.

AU - Fanos, V.

PY - 1999

Y1 - 1999

N2 - Objective: To determine the effects of cefaclor prophylaxis on sensitive urinary biomarkers of renal tubular damage in children with recurrent urinary tract infections. Design: Urinary levels of α1-microglobulin (α1-m) and N-acetyl-β-D-glucosaminidase (NAG) were compared in children with recurrent urinary tract infections on antibacterial prophylaxis with cefaclor and in an untreated control group. Setting: A university paediatric department; patients were followed in a day hospital. Participants and Interventions: Thirty-eight patients (20 males and 18 females aged from 1 to 12 years) with at least two episodes of urinary tract infections in the previous 2 months received cefaclor (20 mg/kg/day in a single bedtime dose) for a minimum of 2 months. After 1 month of treatment all patients underwent BUN and serum creatinine, urine analysis and urine cultures, renal ultrasonography (found to be normal in all cases) and voiding urethrocystography (six cases of vesicoureteric reflux were observed). Results were compared with those from a healthy age-matched untreated control group of 36 children. Main Outcome Measures and Results: In the 32 patients without vesicoureteric reflux, the NAG value was 1.44 ± 1.77 U/mmol creatinine, while the α1-m value was 2.10 ± 1.67 U/mmol creatinine. No significant difference in these parameters was found versus the upper limit of control values (mean values + 2 SD: 1 and 1.6 U/mmol creatinine, respectively). In the six patients who had vesicoureteric reflux, NAG and α1-m values were significantly higher than in controls (p <0.05): 3.08 ± 4.09 and 2.85 ± 3.71 U/mmol creatinine, respectively. Conclusions: Cefaclor prophylaxis was well tolerated at the renal level in children with recurrent urinary tract infections. However, urinary biomarker excretion is increased in the presence of vesicoureteric reflux.

AB - Objective: To determine the effects of cefaclor prophylaxis on sensitive urinary biomarkers of renal tubular damage in children with recurrent urinary tract infections. Design: Urinary levels of α1-microglobulin (α1-m) and N-acetyl-β-D-glucosaminidase (NAG) were compared in children with recurrent urinary tract infections on antibacterial prophylaxis with cefaclor and in an untreated control group. Setting: A university paediatric department; patients were followed in a day hospital. Participants and Interventions: Thirty-eight patients (20 males and 18 females aged from 1 to 12 years) with at least two episodes of urinary tract infections in the previous 2 months received cefaclor (20 mg/kg/day in a single bedtime dose) for a minimum of 2 months. After 1 month of treatment all patients underwent BUN and serum creatinine, urine analysis and urine cultures, renal ultrasonography (found to be normal in all cases) and voiding urethrocystography (six cases of vesicoureteric reflux were observed). Results were compared with those from a healthy age-matched untreated control group of 36 children. Main Outcome Measures and Results: In the 32 patients without vesicoureteric reflux, the NAG value was 1.44 ± 1.77 U/mmol creatinine, while the α1-m value was 2.10 ± 1.67 U/mmol creatinine. No significant difference in these parameters was found versus the upper limit of control values (mean values + 2 SD: 1 and 1.6 U/mmol creatinine, respectively). In the six patients who had vesicoureteric reflux, NAG and α1-m values were significantly higher than in controls (p <0.05): 3.08 ± 4.09 and 2.85 ± 3.71 U/mmol creatinine, respectively. Conclusions: Cefaclor prophylaxis was well tolerated at the renal level in children with recurrent urinary tract infections. However, urinary biomarker excretion is increased in the presence of vesicoureteric reflux.

UR - http://www.scopus.com/inward/record.url?scp=0033378918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033378918&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 461

EP - 466

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 6

ER -